Belgian Pharma Stock News

Wondering if Umicore at €23.80 still offers value after a strong run, or if the easy gains are already behind it? This article focuses on what the current price might imply rather than trying to guess the next move. The stock has returned 6.0% over the past week, 31.7% over the past month, and 28.0% year to date, with a 172.8% return over the last year but declines of 10.1% over three years and 46.8% over five years. These mixed time frame returns are drawing attention back to the...

Proximus (ENXTBR:PROX) is back in focus after first quarter 2026 earnings showed lower sales and net income year over year, while its role in Ekinops’ new Network as a Service offer highlights its wholesale infrastructure. See our latest analysis for Proximus. The recent news around the earnings drop and the NaaS partnership appears to have landed in a mixed way with investors. The share price is at €6.69 after a 1-day share price return of 2.37% and a 90-day share price return that fell...

Proximus PLC ( EBR:PROX ) came out with its quarterly results last week, and we wanted to see how the business is...

Why Anheuser-Busch InBev (ENXTBR:ABI) is back on radar Anheuser-Busch InBev (ENXTBR:ABI) has drawn fresh attention after a recent share move that leaves the stock up about 8.5% over the past month and 2.5% over the past 3 months. See our latest analysis for Anheuser-Busch InBev. For context, Anheuser-Busch InBev’s share price return is up 8.5% over the past month and 27.8% year to date, while the 1 year total shareholder return is 16.6%. This suggests momentum has been building recently. If...

Shareholders might have noticed that Nyxoah SA ( EBR:NYXH ) filed its first-quarter result this time last week. The...

Proximus PLC has reported past first-quarter 2026 results showing sales of €1,510 million and revenue of €1,525 million, with net income of €124 million and basic earnings per share from continuing operations of €0.38, all lower than the same period a year earlier. This broad-based decline across sales, revenue and earnings measures raises questions about how effectively Proximus’s existing efficiency programs and investment plans are offsetting current pressures on its business. We’ll now...

It looks like KBC Group NV ( EBR:KBC ) is about to go ex-dividend in the next 4 days. The ex-dividend date is commonly...

Recent share performance and business context VGP (ENXTBR:VGP) has drawn investor attention after the stock declined 10.2% over the past day, extending falls of 5.6% over the past week and 11.3% over the past month. Those moves come as the €2.21b logistics and semi industrial real estate company, headquartered in Antwerp, continues to generate revenue of €191.99m and net income of €290.44m. This performance is partly supported by its renewable energy activities. See our latest analysis for...

Viohalco (ENXTBR:VIO) drew attention after its stock climbed 13.55% in after-hours trading on EURONEXT on 7 May, as investors focused on its aluminium, copper, cables, and steel operations. See our latest analysis for Viohalco. That after hours jump adds to strong recent momentum, with a 7 day share price return of 16.45% and a 30 day share price return of 23.60%. The 1 year total shareholder return of 218.26% and 5 year total shareholder return of 288.09% underline how sentiment has shifted...

Syensqo SA/NV ( EBR:SYENS ) is about to trade ex-dividend in the next 2 days. Typically, the ex-dividend date is two...

NV Bekaert SA ( EBR:BEKB ) is about to trade ex-dividend in the next 3 days. The ex-dividend date generally occurs two...

argenx (ENXTBR:ARGX) appointed Karen Massey as CEO, and co founder Tim Van Hauwermeiren moved to Chairperson. The company reported strong Q1 results, with accelerating VYVGART sales highlighted as a key driver. An FDA decision on a potential Vyvgart label expansion in seronegative generalized myasthenia gravis is expected soon. argenx focuses on antibody based therapies for autoimmune diseases, with VYVGART already a central product in its portfolio. For investors watching the immunology...

Syensqo cancelled a significant number of shares it had repurchased as part of its ongoing buyback program. The move changes the total number of outstanding shares and voting rights for ENXTBR:SYENS. The action forms part of a broader capital management approach that affects how ownership is distributed across shareholders. For investors watching ENXTBR:SYENS, the cancellation of repurchased shares directly alters the share count that sits behind the current €57.3 price. Recent performance...

As you might know, Anheuser-Busch InBev SA/NV ( EBR:ABI ) just kicked off its latest first-quarter results with some...

Solvay (ENXTBR:SOLB) opened 2026 with Q1 revenue of €1.1 billion and basic EPS of €0.25, alongside trailing twelve month revenue of €4.6 billion and a basic EPS loss of €0.24, setting a mixed backdrop for the latest results. Over recent quarters the company has seen revenue range between €1.1 billion and €1.3 billion per quarter, with basic EPS moving from €0.78 in Q1 2025 through several smaller profits and a loss of €0.90 in Q4 2025 before rebounding in Q1 2026, leaving investors focused on...

Anheuser-Busch InBev (ENXTBR:ABI) opened 2026 with Q1 revenue of US$15.3b and basic EPS of US$1.30, setting a clear benchmark for how the rest of the year might shape up for the brewer’s top and bottom lines. The company has seen quarterly revenue move from US$13.6b in Q1 2025 to US$15.3b in Q1 2026, while basic EPS shifted from US$1.08 to US$1.30 over the same period. This gives you a clean read on how sales and per share earnings are tracking through the cycle. With that backdrop, the...

Earnings snapshot and why it matters now Cofinimmo (ENXTBR:COFB) has just reported first quarter 2026 results, with sales of €87.31 million compared with €86.81 million a year earlier, while net income came in at €53.51 million versus €64.26 million. This mix of slightly higher sales and lower profitability is giving investors fresh numbers to reassess the stock, especially following the recent share price moves over the past month and over the past three months. See our latest analysis for...

Investors may be wondering whether argenx at €678.60 is offering fair value or carrying a premium, particularly after its strong long term share price record. The stock has returned 2.0% over the last 7 days, 4.9% over the last 30 days, a 6.2% decline year to date and 19.8% over the last year, with longer term returns of 86.7% over 3 years and 220.1% over 5 years. Recent coverage around argenx has focused on its position in the biotech sector and investor debate around how much future growth...

Why Xior’s latest quarterly results matter for investors Xior Student Housing (ENXTBR:XIOR) has drawn fresh attention after reporting first quarter 2026 earnings, with sales of €48.67 million and net income of €48.6 million, compared with €43.88 million and €41.95 million a year earlier. See our latest analysis for Xior Student Housing. Despite the stronger first quarter figures, the share price is at €27.6, with a 1 day share price return of 0.91% but a 1 year total shareholder return of...

Umicore (ENXTBR:UMI) has appointed Lily Liu as Chief Financial Officer and Executive Vice President. The company is also creating a new Chief Digital & Transformation Officer role to focus on digitalization and operational excellence. These leadership changes reflect a shift in how Umicore organizes its executive team and oversees transformation initiatives. For investors watching ENXTBR:UMI, the leadership reshuffle comes with the stock at €17.18 and a mixed return profile. The share price...

At its 29 April 2026 shareholder meeting, Anheuser-Busch InBev approved a €1.15 gross total dividend for 2025 and refreshed its board, appointing Fabrizio Freda and Miguel Patricio as directors alongside new Restricted Share Directors. Coupled with a planned US$600.00 million investment in U.S. manufacturing and workforce training, these moves highlight AB InBev’s focus on strengthening operations and supporting shareholder returns. Next, we’ll examine how AB InBev’s newly approved...

ageas (ENXTBR:AGS) has completed the acquisition of the remaining stake in AG Insurance, consolidating full ownership of its Belgian insurance business. The company has issued new and treasury shares to BNP Paribas Cardif, increasing its outstanding share capital and reshaping its shareholder base. ageas is accelerating expansion in India, aiming for a top 10 position through acquisitions and deeper bancassurance partnerships. For investors watching ENXTBR:AGS, these moves come as the share...

Campine NV's ( EBR:CAMB ) robust earnings report didn't manage to move the market for its stock. Our analysis suggests...

As European markets face heightened geopolitical tensions and economic uncertainties, traditionally defensive sectors such as utilities and telecoms have shown resilience, with the pan-European STOXX Europe 600 Index recently experiencing a decline. In this environment, dividend stocks can offer a measure of stability and potential income for investors seeking to navigate these challenging times.